Affimed Announces Updated AFM13 Clinical Data Presentation at the American Society of Hematology Annual Meeting, Demonstrating ...
AFM13 monotherapy was well tolerated and reached an Objective Response Rate of 42 percent among heavily pretreated patients with R/R CD30-positive lymphoma with cutaneous presentation Immunological analyses revealed that innate cell engagers modulate NK …